0001104659-18-074338.txt : 20181221
0001104659-18-074338.hdr.sgml : 20181221
20181221124634
ACCESSION NUMBER: 0001104659-18-074338
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181221
FILED AS OF DATE: 20181221
DATE AS OF CHANGE: 20181221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Andriole Michael T.
CENTRAL INDEX KEY: 0001698751
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35050
FILM NUMBER: 181248555
MAIL ADDRESS:
STREET 1: C/O ENDOCYTE, INC.
STREET 2: 3000 KENT AVENUE, SUITE A1-100
CITY: WEST LAFAYETTE
STATE: IN
ZIP: 47906
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENDOCYTE INC
CENTRAL INDEX KEY: 0001235007
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 KENT AVE STE A1-100
CITY: WEST LAFAYETTE
STATE: IN
ZIP: 47906
BUSINESS PHONE: 7654637175
MAIL ADDRESS:
STREET 1: 3000 KENT AVE STE A1-100
CITY: WEST LAFAYETTE
STATE: IN
ZIP: 47906
4
1
a4.xml
4
X0306
4
2018-12-21
1
0001235007
ENDOCYTE INC
ECYT
0001698751
Andriole Michael T.
3000 KENT AVE., SUITE A1-100
WEST LAFAYETTE
IN
47906
0
1
0
0
Chief Financial Officer
Common Stock
2018-12-21
4
D
0
52582
24.00
D
0
D
Common Stock
2018-12-21
4
D
0
37500
24.00
D
0
D
Common Stock
2018-12-21
4
D
0
37500
24.00
D
0
D
Common Stock
2018-12-21
4
D
0
25000
24.00
D
0
D
Stock Option (right to buy)
2.22
2018-12-21
4
D
0
75000
21.78
D
2027-02-20
Common Stock
75000
0
D
Stock Option (right to buy)
3.01
2018-12-21
4
D
0
50000
20.99
D
2028-02-08
Common Stock
50000
0
D
Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
This restricted stock unit ("RSU") award, which originally consisted of 50,000 RSUs and of which 12,500 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 20, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
This RSU award, which originally consisted of 75,000 RSUs and of which 37,500 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 20, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
/s/ Beth A. Taylor, Attorney-in-Fact for Michael T. Andriole (power of attorney previously filed)
2018-12-21